Products Containing CAVADEX®
CAVADEX can only be absorbed via intravenous administration or as an enema.
Cyclodextrins taken orally are destroyed in the gut and have no effect on health.
Remchol enema tubes
Remchol for home use
RemChol delivers CAVADEX® via an enema.
Each tube contains 8 grams of CAVADEX® with over 2 grams absorbed into the blood stream with every treatment.
Remchol tubes can be administered as often as one tube a day.
Back in stock
$249.00
PLUS POSTAGE
1 month supply (32 tubes)
After You Click Buy Now, You Will Be Able To Change The Number Of Boxes Desired On The Left Hand Side Of The Next Page Next To "Qty".
Remchol enema tubes. 3 month supply
Remchol for home use
Over 180 grams of CAVADEX® absorbed over 3 months.
Each tube contains 8 grams of CAVADEX® with over 2 grams absorbed into the blood stream with every treatment.
Remchol tubes can be administered as often as one tube a day.
Back in stock
$649.00
PLUS POSTAGE
3 month supply (96 tubes)
After You Click Buy Now, You Will Be Able To Change The Number Of Boxes Desired On The Left Hand Side Of The Next Page Next To "Qty".
CAVADEX® reduces atherosclerosis
Heart disease and treatment explained.
Over 25% of Americans die from heart attack and heart disease
Coronary artery disease is the clogging or blockage of the coronary arteries caused by atherosclerosis.
High cholesterol diets, lack of exercise or your genetics can cause cholesterol to build up in the arteries. 655,000 Americans die each year from heart disease.
In 2016, German scientists discovered a compound “Cyclodextrin” that reduced arterial plaque in mice.
Our company researched cyclodextrins and engineered a specific cyclodextrin with enhanced cholesterol transport capabilities.
This new cyclodextrin "CAVADEX®" has shown to reduce cholesterol and atherosclerosis plaque in as little as 4 weeks.
CAVADEX® circulates around the vascular system, sucking up cholesterol and other lipids and transporting it out via the urinary system.
CAVADEX
The only cyclodextrin proven safe in the treatment of atherosclerosis
Science Articles
Nature
Cyclodextrin reprogrammed the cells in plaques, leading to increased transport of the dissolved cholesterol away from the plaques...
Science Daily
Cyclodextrin dissolves cholesterol crystals and reduces atherosclerotic plaques...
Huffington Post
can actually solubilize cholesterol and dissolve the plaques...
Science Daily
Soaked up cholesterol and removed it...
Norwegian University of Science and Technology
have the potential in lowering deaths caused by atherosclerosis...
CAVADEX® removes plaque and cholesterol
plaque reduced in just 4 weeks
A recent study by the University Hospital in Bonn, Germany discovered that cyclodextrin melts away cholesterol crystals (the main cause of arterial plaque that clogs arteries) and reduced existing plaque within just 4 weeks. The cyclodextrin bound to and dissolved the cholesterol crystals from the plaque of mice, leading to transport of the dissolved cholesterol away from the plaques. The same effects were seen in human plaque samples treated with cyclodextrin.
Article : Cyclodextrin promotes atherosclerosis regression via macrophage reprogrammingImprove Liver function
Another study by the University of Texas Southwestern Medical Center, Dallas, Texas, shows the treatment of Npc1-deficient mice slows cholesterol sequestration in major organs and improves liver function. This study shows that cyclodextrin is effective in mobilizing entrapped cholesterol in late stage NPC disease leading to improved liver function.
Article : Systemic administration of 2-hydroxypropyl-B-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.Cyclodextrin has shown to extend lifespan by almost 10% in mice
Mice treated with CAVADEX® showed higher neurological scores than compared with the mice given saline only..
Mice on CAVADEX® lived 10% longer.
CAVADEX® cleares the vascular system and can extend lifespan.
In 2014 at the University of Texas Southwest Medical Center, a study was conducted on the effects of Cyclodextrin administered to mice.
They studied the lifespan of mice treated systemically with either saline or Cyclodextrin at weekly
intervals starting at 49 days of age until death. In each case, half of the males and females were
given Cyclodextrin and the remaining mice received only saline.
During the study, the mice were graded on their neurological function. There were no gender related differences in the neurological scores. This score, which broadly measures neurological
function, declines as the animal’s condition deteriorates.
It is clear that Cyclodextrin treated mice showed higher neurological scores than compared with
the mice given saline only.
All the mice given saline only had died by 98 days whereas the majority of those receiving
Cyclodextrin died in the week following. This shows an almost 10% improvement in lifespan.
The human trial of CAVADEX conducted by Cholrem has consistantly shown the scientific evidence proving the benefits of Cyclodextrin on mice also has simular benefits on humans. It would
be fair to assume that based on the science, humans treated with CAVADEX would also experience a simular benefit of lifespan extention as the mice.
Cyclodextrin Publications
About Cyclodextrins
Molecular mechanism of cyclodextrin mediated cholesterol extraction
Rationale for Therapeutic Use of Lipid Transport Mediators in Renal Disease
Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.
Systemic and renal lipids in kidney disease development and progression
Lipid biology of the podocyte--new perspectives offer new opportunities.
Renal lipid metabolism and lipotoxicity.
Cyclodextrins and Non-renal Diseases
Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.
Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease.
Cyclodextrins and Renal Disease
Cyclodextrin Protects Podocytes in Focal Segmental Glomerulosclerosis (FSGS)
Cyclodextrin improves renal function in experimental alport syndrome.